Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report.
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
24
03
2023
accepted:
19
07
2023
revised:
29
06
2023
medline:
23
10
2023
pubmed:
3
8
2023
entrez:
2
8
2023
Statut:
ppublish
Résumé
We present the first evidence that sub-anesthetic ketamine infusions for treatment resistant depression (TRD) may facilitate deprescription of long-term benzodiazepine/z-drugs (BZDRs). Long-term BZDR prescriptions are potentially harmful yet common, partly because of challenging withdrawal symptoms. Few pharmacological interventions have evidence for facilitating BZDR discontinuation, and none in patients actively suffering from TRD. In this ambi-directional cohort study, discontinuation of long-term (>6 month) BZDRs was attempted in 22 patients with severe unipolar or bipolar TRD receiving a course of six subanesthetic ketamine infusions over four weeks. We investigated the rates of successful BZDRs deprescription, trajectories of acute psychological withdrawal symptoms, and subsequent BZDRs abstinence during a mean follow-up of 1 year (primary outcome). Clinically significant deteriorations in depression, anxiety, sleep, and/or suicidality during the acute BZDR discontinuation phase were measured by repeated standardized scales and analyzed by latent growth curve models and percent correct classification analysis. Of the 22 eligible patients, all enrolled in this study and 91% (20/22) successfully discontinued all BZDRs by the end of the 4-week intervention, confirmed by urinary analyses. Less than 25% of discontinuers experienced any significant worsening of anxiety, depression, sleep difficulties, or suicidality during treatment. During follow-up (mean [range] duration, 12 [3-24] months), 64% (14/22) of patients remained abstinent from any BZDRs. These preliminary results suggest that ketamine infusions for TRD may facilitate the deprescription of BZDRs, even in patients with active depressive symptoms and significant comorbidity. Further investigation is warranted into this potential novel application of ketamine.
Identifiants
pubmed: 37532888
doi: 10.1038/s41386-023-01689-y
pii: 10.1038/s41386-023-01689-y
pmc: PMC10579413
doi:
Substances chimiques
Ketamine
690G0D6V8H
Benzodiazepines
12794-10-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1769-1777Informations de copyright
© 2023. The Author(s).
Références
Neuropsychiatr Dis Treat. 2021 Jul 15;17:2347-2357
pubmed: 34290505
Behav Res Methods. 2018 Aug;50(4):1398-1414
pubmed: 29067672
J Psychiatr Res. 2019 Sep;116:147-150
pubmed: 31238203
Health Qual Life Outcomes. 2018 Mar 13;16(1):49
pubmed: 29534726
J Pers Assess. 1996 Dec;67(3):588-97
pubmed: 8991972
Ther Adv Psychopharmacol. 2022 Apr 25;12:20451253221082386
pubmed: 35499041
Am J Psychiatry. 2021 May 1;178(5):383-399
pubmed: 33726522
N Engl J Med. 2017 Mar 23;376(12):1147-1157
pubmed: 28328330
Ther Adv Psychopharmacol. 2018 May;8(5):147-168
pubmed: 29713452
Int J Environ Res Public Health. 2021 Sep 15;18(18):
pubmed: 34574645
J Clin Psychiatry. 2010;71 Suppl E1:e04
pubmed: 20371031
Am J Psychiatry. 2018 Feb 01;175(2):150-158
pubmed: 28969441
JAMA Psychiatry. 2022 Jul 1;79(7):639-640
pubmed: 35583897
J Nerv Ment Dis. 2015 Sep;203(9):659-63
pubmed: 26241407
Psychother Psychosom. 2021;90(1):41-48
pubmed: 32854103
Jpn J Pharmacol. 1999 Sep;81(1):1-6
pubmed: 10580363
Handb Exp Pharmacol. 2019;253:337-358
pubmed: 28939975
Braz J Psychiatry. 2013 Oct-Dec;35(4):416-31
pubmed: 24402217
Am J Psychiatry. 2017 Jan 1;174(1):18-25
pubmed: 27609243
Psychiatry Res. 2015 Feb 28;225(3):368-73
pubmed: 25571773
Cochrane Database Syst Rev. 2019 Jun 03;6:CD001026
pubmed: 31158298
J Consult Clin Psychol. 1991 Feb;59(1):12-9
pubmed: 2002127
Arch Gen Psychiatry. 1990 Oct;47(10):908-15
pubmed: 2222130
CNS Drugs. 2004;18(1):37-48
pubmed: 14731058
Int J Neuropsychopharmacol. 2019 Apr 1;22(4):270-277
pubmed: 30722037
Neurotox Res. 2018 Feb;33(2):422-432
pubmed: 28936791
BMC Psychiatry. 2020 Nov 17;20(1):541
pubmed: 33203427
Psychol Addict Behav. 2014 Mar;28(1):154-62
pubmed: 23276315
JAMA Psychiatry. 2017 Jul 1;74(7):747-755
pubmed: 28593281
Am J Psychiatry. 2022 Feb;179(2):90-93
pubmed: 35105164
Br J Clin Pharmacol. 2014 Feb;77(2):295-301
pubmed: 22882333
Brain Res. 1998 Apr 20;790(1-2):82-90
pubmed: 9593834
BMC Psychiatry. 2022 Oct 3;22(1):634
pubmed: 36192794
J Gen Intern Med. 2019 Sep;34(9):1833-1840
pubmed: 31240606
Ther Adv Psychopharmacol. 2021 Dec 15;11:20451253211056743
pubmed: 34925757
Hum Psychopharmacol. 2003 Jan;18(1):1-20
pubmed: 12532311
Cochrane Database Syst Rev. 2015;(5):CD009652
pubmed: 26106751
Hum Psychopharmacol. 2003 Dec;18(8):603-10
pubmed: 14696019
Cureus. 2021 Dec 2;13(12):e20114
pubmed: 35003959
Addiction. 1994 Nov;89(11):1455-9
pubmed: 7841856
J Clin Psychiatry. 2015 Mar;76(3):247-52
pubmed: 25271445
Neuropsychiatr Dis Treat. 2019 Dec 09;15:3411-3417
pubmed: 31849475
J Consult Clin Psychol. 1979 Apr;47(2):343-52
pubmed: 469082
J Psychiatr Res. 2014 Nov;58:161-6
pubmed: 25169854
J Subst Abuse Treat. 1991;8(1-2):19-28
pubmed: 1675688
Addiction. 2019 Jul;114(7):1274-1282
pubmed: 30938020
Br J Psychiatry. 2001 Apr;178:317-24
pubmed: 11282810
J Manag Care Spec Pharm. 2022 Jan;28(1):58-68
pubmed: 34949119
Drug Alcohol Depend. 2022 Oct 1;239:109606
pubmed: 36087563
Pharmacol Ther. 2003 May;98(2):171-95
pubmed: 12725868
J Affect Disord. 2002 Jul;70(2):133-41
pubmed: 12117625
Cochrane Database Syst Rev. 2018 Mar 15;3:CD011481
pubmed: 29543325